Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s12916-015-0404-6 http://scihub22266oqcxt.onion/10.1186/s12916-015-0404-6 C4499896!4499896 !26170121     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26170121 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       BMC+Med 2015 ; 13 (ä): 163 Nephropedia Template TP {{tp|p=26170121 |t=2015. Amyloid imaging for dementia in clinical practice |pdf=|usr=}}{{26170121 }} gab.com Text Amyloid imaging for dementia in clinical practice JO: BMC Med http://www.kidney.de/pget.php?&tw=1&pmid=26170121 #FOAvip In vivo imaging of brain amyloid using positron emission tomography (PET) scanning is widely used in research studies of dementia, with three amyloid PET ligands being licenced for clinical use. The main clinical use of PET is to help confirm or exclude the likely diagnosis of Alzheimer's disease in challenging cases, where diagnostic uncertainty remains after current clinical and investigative work up. Whilst diagnostically valuable in such select cases, much wider clinical adoption, especially for very early disease, will be limited by both cost and the lack of a currently effective disease-modifying treatment that requires such early case identification. The use of amyloid imaging to appropriately stratify subjects for prognostic studies and therapeutic trials should increase the efficiency and potentially shorten the time of such studies, and its use combined with other biomarkers and genetics will likely lead to new ways of defining and classifying the dementias. Twit Text FOAVip Amyloid imaging for dementia in clinical practice ????BMC Med http://www.kidney.de/pget.php?&tw=1&pmid=26170121 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26170121 #FOAvip English Wikipedia <ref>{{Cite pmid|26170121 }}</ref> Amyloid imaging for dementia in clinical practice #MMPMID26170121 O'Brien JT ; Herholz K BMC Med 2015[Jul]; 13 (ä): 163 PMID26170121 show ga In vivo imaging of brain amyloid using positron emission tomography (PET) scanning is widely used in research studies of dementia, with three amyloid PET ligands being licenced for clinical use. The main clinical use of PET is to help confirm or exclude the likely diagnosis of Alzheimer's disease in challenging cases, where diagnostic uncertainty remains after current clinical and investigative work up. Whilst diagnostically valuable in such select cases, much wider clinical adoption, especially for very early disease, will be limited by both cost and the lack of a currently effective disease-modifying treatment that requires such early case identification. The use of amyloid imaging to appropriately stratify subjects for prognostic studies and therapeutic trials should increase the efficiency and potentially shorten the time of such studies, and its use combined with other biomarkers and genetics will likely lead to new ways of defining and classifying the dementias. |Alzheimer Disease/complications/*diagnostic imaging [MESH] |Amyloidogenic Proteins/*analysis [MESH] |Dementia/*diagnostic imaging/etiology [MESH] |Humans [MESH] |Positron-Emission Tomography/*methods [MESH]Amyloid imaging for dementia in clinical practice (epmc).pdf DeepDyve Pubget Overpricing